Multi-user equipment approved in grant 2013/07600-3: High Performance Liquid Chromatograph

• Grant number: 21/13118-6
• Support Opportunities: Multi-user Equipment Program
• Start date: February 01, 2022
• End date: January 31, 2029
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Principal Investigator: Vanderlan da Silva Bolzani
• Grantee: Vanderlan da Silva Bolzani
• Host Institution: Instituto de Química (IQ). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated research grant: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery, AP.CEPID
• EMU web page: Página do Equipamento Multiusuário não informada
• Type of equipment: Caracterização de Materiais - Análises Químicas - Cromatrografia líquida
• Manufacturer: Fabricante não informado
• Model: Modelo não informado

Abstract

The Center for Research and Innovation in Biodiversity and Drug Discovery (CIBFar) is a joint initiative resulting from existing collaborative research projects, including the Physics Institute of São Carlos (IFSC) and the School of Pharmaceutical Sciences of Ribeirão Preto at the University of São Paulo (USP), the Institute of Chemistry at the State University of São Paulo (UNESP), the Institute of Chemistry at the State University of Campinas (UNICAMP), and the Department of Chemistry at the Federal University of São Carlos (UFSCar). The major goals of this Center are to perform basic and applied science and to develop technologies, such as in vitro and in vivo biological and pharmacological evaluations, for all areas of biodiversity and drug discovery that rely on state-of-the-art methods in medicinal chemistry, natural products chemistry, synthetic organic chemistry, and molecular and structural biology. Strategic partnerships with the private sector are always sought, particularly with national and international pharmaceutical companies and research institutes within the health sector. The ultimate goals are the development of clinical candidates for tropical infectious diseases, cancer and central nervous system disorders and the development of new synthetic routes to generic drugs. On the educational front, the Center also relies on the considerable experience that has been acquired over the last eleven years from our previous CEPID-FAPESP. Intensive work has been done on outreach programs focused on science education from elementary school to high school. CIBFar has the benefit of joining research groups in a modern multidisciplinary setting while also providing access to a well-established infrastructure with extensive experience in the areas of technical, financial, educational, technological and executive management. (AU)